Next Article in Journal
Neuropathic Pain: Biomolecular Intervention and Imaging via Targeting Microglia Activation
Next Article in Special Issue
Characterization of Phosphorylation Status and Kinase Activity of Src Family Kinases Expressed in Cell-Based and Cell-Free Protein Expression Systems
Previous Article in Journal
Sensitivity of Acute Myelocytic Leukemia Cells to the Dienone Compound VLX1570 Is Associated with Inhibition of the Ubiquitin-Proteasome System
Previous Article in Special Issue
Phosphorylated Osteopontin Secreted from Cancer Cells Induces Cancer Cell Motility
 
 
Review
Peer-Review Record

The Regulation of Rab GTPases by Phosphorylation

Biomolecules 2021, 11(9), 1340; https://doi.org/10.3390/biom11091340
by Lejia Xu 1,†, Yuki Nagai 1,†, Yotaro Kajihara 1,†, Genta Ito 2,3,*,† and Taisuke Tomita 1,3,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Biomolecules 2021, 11(9), 1340; https://doi.org/10.3390/biom11091340
Submission received: 17 August 2021 / Revised: 8 September 2021 / Accepted: 9 September 2021 / Published: 10 September 2021
(This article belongs to the Collection Recent Advances in Protein Phosphorylation)

Round 1

Reviewer 1 Report

The review by Xu et al., is well written and informative. The topic is relevant. The figures are very good. I have some points below.

The abstract is missing a full stop toward the end.

In the section of the discovery of Rab phosphorylation by LRRK2, it is stated that a Lewy body appears in the remaining dopaminergic neurons. As worded this seems not correct. Many Lewy bodies are found throughout PD brain and Lewy pathology precedes dopaminergic neuron loss.

Italics are usually used when referring to genes.

The section on Rab phosphorylation by LRRK2 in human samples should include the studies of Atashrazm et al., Mov Disord 2019 and Wang et al., Sci Rep 2021. Are there any studies looking at LRRK2 mediated Rab phosphorylation in human tissues besides blood cells (ie brain).

In this sentence in the section of the proposed role of LRRK2 in a-syn propagation – “Moreover, none of the three LRRK2 inhibitors tested failed to 281 reduce α-synuclein pathology induced by the treatment of neurons with pre-formed α- 282 synuclein fibrils.” I think this meant to say all of the 3 inhibitors tested failed to reduce a-syn pathology? This section could also benefit from the authors providing more insight into why they think there are discrepancies. There are other studies suggesting LRRK2 inhibitors can reduce a-syn pathology that have not been cited, and importantly many of these are in human iPS cell models rather than mouse models.

In the section on Rab phosphorylation by TBK1, the authors could mention that TBK1 is also genetically linked to neurodegenerative diseases. TBK1 also phosphorylates LRRK2 at Ser935!

It is mentioned that there are many (60) Rab proteins but are these all ubiquitously expressed, or may certain Rabs have functions in certain cells?

LRRK2 and LRRK1 are both RIP kinase family members, could other Rip kinase family members (which are all stress-sensing kinases) also phosphorylate Rabs?

What is known about the dephosphorylation of Rab proteins? Phosphorylation is normally a reversible process but this does not seem to be covered in the review.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

Xu et al. have written a comprehensive review of the role that phosphorylation plays in regulating the activity of Rab GTPases and the implications for disease, Parkinson’s in particular. The recent discovery that LRRK2 phosphorylates a number of Rab GTPases has sparked increasing interest in what has traditionally been an understudied aspect of Rab biology. This is a very well written, timely and important review and I recommend that it be accepted for publication with the following very minor revisions.

Line 21: missing full stop.

Line 28: ‘The Rab family is a member…..’

Line 31: ‘Like other small GTPases, Rab GTPases exist….’

Lines 102/104: Type fourteen instead of 14.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop